ASCO 2012 - American Society of Clinical Oncology - June 2012 - Chicago
An Expert Explains Positive News on CML VIDEO
June 27, 2012, Patient Power
The Leukemia Race to Heat up at 2012's ASCO Conference
May 31, 2012, SmallCap Network
Novartis showcases ongoing research at ASCO to help patients fight various cancers, including updated data in advanced breast cancer
May 31, 2012, Reuters
Ariad Announces Updated Findings from Pivotal Pace Trial of Ponatinib to Be Presented at Annual Meeting of American Society of Clinical Oncology
May 16, 2012, Minyanville
Bristol Myers Squibb Co. : New Data from Bristol-Myers Squibb Oncology Portfolio to be Presented at 2012 American Society of Clinical Oncology (ASCO) Annual Meeting
May 16, 2012, 4-traders
Pfizer To Present New Data In Advanced Kidney, Lung And Hematologic Cancers At 2012 ASCO Annual Meeting
May 14, 2012, Fierce Pharma
June 27, 2012, Patient Power
The Leukemia Race to Heat up at 2012's ASCO Conference
May 31, 2012, SmallCap Network
Novartis showcases ongoing research at ASCO to help patients fight various cancers, including updated data in advanced breast cancer
May 31, 2012, Reuters
Ariad Announces Updated Findings from Pivotal Pace Trial of Ponatinib to Be Presented at Annual Meeting of American Society of Clinical Oncology
May 16, 2012, Minyanville
Bristol Myers Squibb Co. : New Data from Bristol-Myers Squibb Oncology Portfolio to be Presented at 2012 American Society of Clinical Oncology (ASCO) Annual Meeting
May 16, 2012, 4-traders
Pfizer To Present New Data In Advanced Kidney, Lung And Hematologic Cancers At 2012 ASCO Annual Meeting
May 14, 2012, Fierce Pharma
Analysis of imatinib (IM)-related, low-grade (LG), non-hematologic (heme) adverse events (AEs) in patients (pts) with chronic myeloid leukemia (CML) switched to nilotinib (NIL): ENRICH study update.
PACE: A pivotal phase II trial of ponatinib in patients with CML and Ph+ALL resistant or intolerant to dasatinib or nilotinib, or with the T315I mutation.
Ariad leukemia drug helps chronic trial patients
New drugs may help immune system fight cancer
Monitoring and switching patterns in chronic myelogenous leukemia (CML) pts treated with imatinib (IM): A chart review analysis.
Elderly MDS Patients May Achieve Long-Term Survival From Stem Cell Transplantation (ASCO 2012)
ASCO: Ponatinib Provides New Option for Heavily Treated Patients With CML
PACE: A pivotal phase II trial of ponatinib in patients with CML and Ph+ALL resistant or intolerant to dasatinib or nilotinib, or with the T315I mutation.
Ariad leukemia drug helps chronic trial patients
New drugs may help immune system fight cancer
Monitoring and switching patterns in chronic myelogenous leukemia (CML) pts treated with imatinib (IM): A chart review analysis.
Elderly MDS Patients May Achieve Long-Term Survival From Stem Cell Transplantation (ASCO 2012)
ASCO: Ponatinib Provides New Option for Heavily Treated Patients With CML
